TOKYO and BOSTON, July 18, 2023 /PRNewswire/ -- Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new program to develop functional chemicals with synthetic biology and expand upon the companies' existing biomanufacturing partnership.

Sumitomo Chemical and Ginkgo Bioworks have been collaborating since 2021 using Ginkgo's synthetic biology platform for the production of products in industries ranging from personal care and cosmetics, to agriculture and pharma. Today's announcement marks the start of a third project between the companies which aims to enable the mass production of functional chemicals via fermentation.

As part of this latest project, Ginkgo Bioworks plans to utilize its strain design technology to develop a microbial strain and related fermentation process to produce the target molecule, while Sumitomo Chemical will develop the manufacturing process and its scale-up for commercialization. By mass-producing the functional chemicals through microbial fermentation instead of traditional fossil fuel-based chemical synthesis, the companies aim to provide products with a lower carbon footprint that contribute toward a carbon-neutral society.

As the rapid development of biotechnology and digital technologies continues, synthetic biology, in which organisms are genetically engineered to express desired functions, is attracting more attention in various fields. In particular, leaders in the chemical industry expect synthetic biology to have the potential to replace raw materials and create energy-saving processes, replacing the current high-temperature, high-pressure processes that use petroleum as a raw material.

"In the field of chemicals, there is an urgent need to develop products and processes with low environmental impact, and we believe that the use of synthetic biology will meet this need," said Hiroshi Ueda, Executive Vice President of Sumitomo Chemical. "By strengthening our collaboration with Ginkgo Bioworks as a partner in synthetic biology, we aim to accelerate the development of innovative technologies that could be a game changer for the chemical industry and ultimately consumers."

"Sumitomo Chemical is a valued long-term partner to Ginkgo Bioworks, and we are as excited as ever about our work together to introduce bio-based products across multiple industries. Our ongoing relationship provides an invaluable opportunity to generate continuous learning and create scalable processes that allow our partners to make more and more sustainable products through synthetic biology," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "We're so proud of the fruits already borne by our unique collaboration, and we look forward to continuing to work through the pipeline of products of interest that we share with our fantastic colleagues at Sumitomo Chemical."

About Sumitomo Chemical

Headquartered in Tokyo, Japan, Sumitomo Chemical is one of Japan's leading chemical companies, offering a diverse range of products globally in the fields of Essential Chemicals & Plastics, Energy & Functional Materials, IT-related Chemicals, Health & Crop Sciences, and Pharmaceuticals. The company's consolidated net sales for the fiscal year of 2022 were JPY 2.9 trillion, and the number of employees is about 33,500 as of March 31, 2023. For additional information, visit the company's website athttps://www.sumitomo-chem.co.jp/english/.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visitginkgobioworks.com andconcentricbyginkgo.com, read ourblog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), orLinkedIn.

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on May 10, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

GINKGO BIOWORKS INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

GINKGO BIOWORKS MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

SUMITOMO CHEMICAL CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.